What is intimal sarcoma?
Intimal sarcoma is a very rare cancer that grows from the inner lining of large blood vessels. This lining is called the intima, which gives the tumour its name.
The tumour most often starts in the pulmonary artery, the large vessel that carries blood from the heart to the lungs. It can also arise in the aorta, the main artery of the body, and in the heart, where similar tumours are often called undifferentiated cardiac sarcomas.
Because it grows inside the vessel, intimal sarcoma behaves like a blood clot. It narrows or blocks the artery and is very often mistaken for a pulmonary embolism at first. Many people receive blood-thinning treatment for months before the true cause is found (Assi, Kattan and Rassy, 2020).
Most intimal sarcomas carry extra copies of the MDM2 gene, a change that helps pathologists confirm the diagnosis and that new medicines are trying to target (Koelsche et al., 2021). Treatment usually combines major surgery with chemotherapy and sometimes radiotherapy, but the outlook is serious.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Sarcoma arising from the inner lining of large arteries or the heart |
| How common | Extremely rare; only a few hundred cases of pulmonary artery sarcoma have been described in detail |
| Typical age | Adults; average about 45-55 years |
| Sex | Men and women affected about equally, with a slight female excess in some reports |
| Main sites | Pulmonary trunk and main pulmonary arteries; aorta; left atrium of the heart |
| Key gene change | MDM2 amplification, often with CDK4 and PDGFRA |
| Common mix-up | Pulmonary embolism or chronic thromboembolic disease |
| Main treatment | Surgery, chemotherapy, radiotherapy |
| Outlook | Serious; best when the tumour can be removed completely |
2. Where intimal sarcoma grows
| Site | Notes |
|---|---|
| Pulmonary artery | The most common site; usually starts in the main trunk and spreads along the branches |
| Pulmonary valve and right ventricle | Tumour may grow backwards into the heart |
| Aorta | Usually the descending thoracic or abdominal aorta; may cause blockages downstream |
| Heart (left atrium) | Tumours here share the same MDM2 gene change and are now regarded as closely related |
| Other large arteries | Very rarely, the iliac or femoral arteries |
3. Causes and risk factors
The cause of intimal sarcoma is not known. No link with smoking, diet, lifestyle, previous clots or blood thinners has been found.
Gene changes
| Gene change | Frequency | Notes |
|---|---|---|
| MDM2 amplification | Most cases | Switches off the p53 protective pathway; the key diagnostic marker |
| CDK4 amplification | Many cases | Promotes cell division |
| PDGFRA amplification or activation | Many cases | A growth-signalling gene; a possible drug target |
| EGFR amplification | Some cases | Another growth-signalling gene |
| MDM4 or CDK6 amplification | A small number, usually without MDM2 gain | Described in heart and vessel sarcomas (Koelsche et al., 2021) |
These changes are acquired in the tumour cells. They are not inherited and do not pass to children.
4. How does it look
On scans
Intimal sarcoma usually looks like a filling defect inside the artery, which is why it is often confused with a clot.
| Feature | What it suggests |
|---|---|
| Defect that fills the whole width of the artery | Sometimes called the wall-eclipsing sign; favours tumour over clot |
| Spread backwards towards the heart or valve | Unusual for a clot |
| Lobulated, bulging edge | Favours tumour |
| Enhancement after contrast on CT or MRI | Shows the mass has a blood supply, unlike a clot |
| High uptake on PET-CT | Suggests an active tumour |
| Growth through the vessel wall | Indicates invasion of nearby tissue |
| No improvement on blood thinners | A strong clue that the defect is not a clot |
During surgery
| Feature | Description |
|---|---|
| Shape | A polypoid or sausage-like mass growing along the inside of the artery |
| Colour | Grey, white or yellowish, often mixed with real clot |
| Consistency | Soft and jelly-like to firm and rubbery |
| Attachment | Firmly stuck to the vessel wall at its base |
Under the microscope
| Feature | Description |
|---|---|
| Cells | Spindle-shaped or rounded cells with very abnormal nuclei |
| Pattern | Usually undifferentiated; sometimes areas of bone, cartilage or muscle-like tissue |
| Background | Myxoid (jelly-like) areas and clot are common |
| Stains | MDM2 nuclear staining in most cases; CDK4 often positive |
| Molecular test | FISH or sequencing shows MDM2 amplification |
5. Symptoms
Symptoms are caused by blockage of blood flow and depend on which vessel is involved. They usually develop gradually over weeks or months.
Pulmonary artery sarcoma
| Symptom | Notes |
|---|---|
| Breathlessness | The most common symptom, slowly worsening |
| Chest pain | Often dull or pressing |
| Cough | Sometimes with blood (haemoptysis) |
| Tiredness and reduced exercise capacity | From strain on the right side of the heart |
| Ankle swelling and fainting | Signs of right heart failure |
| Fever, night sweats and weight loss | General symptoms seen in some people |
| Palpitations | Uneven heartbeat |
Aortic sarcoma
- Pain in the legs when walking, cold limbs or numbness, from blockage or small clots travelling downstream
- Sudden tummy pain if bowel arteries are blocked
- Back pain or a pulsating lump if the aorta swells
- High blood pressure if the kidney arteries are affected
Heart (left atrial) sarcoma
- Breathlessness, especially lying flat
- Palpitations
- Stroke-like symptoms if fragments travel to the brain
Clues that a “clot” might be a tumour
- Symptoms keep getting worse despite proper blood-thinning treatment
- There is no obvious cause for a clot, such as a leg vein thrombosis
- The person has fever, weight loss or a high ESR or CRP
- Scans show a bulging mass extending into the heart or through the vessel wall
When to seek medical advice
Seek urgent care for sudden breathlessness, chest pain, fainting or coughing blood. If you have been treated for a pulmonary embolism and are not improving, ask your doctor whether further imaging is needed.
6. Diagnosis
| Test | Purpose |
|---|---|
| CT pulmonary angiogram | Usually the first test; shows a filling defect |
| Cardiac MRI with contrast | Helps separate tumour from clot |
| PET-CT | Shows active tumour and looks for spread |
| Echocardiogram | Assesses the heart valves and the pressure in the lungs |
| Biopsy | Taken through a catheter inside the vessel, by needle, or during surgery |
| MDM2 testing | Immunohistochemistry and FISH confirm the diagnosis |
| Staging scans | CT of chest, abdomen and pelvis, sometimes brain imaging |
Getting tissue from inside the pulmonary artery can be difficult. In many people the diagnosis is made only at surgery for presumed chronic clots (Assi, Kattan and Rassy, 2020).
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Acute pulmonary embolism | Sudden onset; improves with blood thinners |
| Chronic thromboembolic pulmonary hypertension | Thin webs and narrowing rather than a bulging mass |
| Other sarcomas spreading into vessels | A main tumour is found elsewhere |
| Cardiac myxoma | Benign heart tumour; different appearance and no MDM2 gain |
Why diagnosis is often delayed
Studies of pulmonary artery sarcoma show that the right diagnosis is frequently made several months after the first symptoms. There are a few reasons for this:
- Pulmonary embolism is thousands of times more common, so doctors reasonably treat it first
- The tumour often contains real clot on its surface, which hides the mass beneath
- Standard CT scans show only a dark shape inside the artery, without telling what it is made of
- The symptoms, such as breathlessness and tiredness, are common and non-specific
Specialist pulmonary hypertension centres now look carefully for tumour features in anyone with unexplained or worsening clots in the main pulmonary arteries.
7. Treatment
Treatment should take place in a specialist centre with cardiothoracic surgeons, sarcoma oncologists and radiologists experienced in this tumour.
Surgery
| Operation | Notes |
|---|---|
| Pulmonary endarterectomy | Tumour is cleared from inside the arteries; restores blood flow and relieves symptoms |
| Resection of the artery with graft | Removes the involved vessel segment and replaces it |
| Removal of part or all of a lung | If the tumour extends into the lung |
| Valve replacement | If the pulmonary valve is involved |
| Aortic resection and graft | For aortic tumours |
| Removal of heart tumour | For left atrial disease, sometimes with heart reconstruction |
Surgery provides the best chance of long-term control, but complete removal is often not possible because the tumour spreads along the vessel.
Chemotherapy
| Situation | Usual drugs |
|---|---|
| Before or after surgery | Doxorubicin, often with ifosfamide |
| Advanced disease | Doxorubicin-based treatment first; gemcitabine and docetaxel later |
| Clinical trials | MDM2 inhibitors, CDK4/6 inhibitors and PDGFRA-targeted drugs are being studied (López Subires, Amondarain Amenabar and Valverde, 2026) |
Radiotherapy
Radiotherapy may be given after surgery to reduce the chance of the tumour returning, or to relieve symptoms when surgery is not possible.
Side effects
| Treatment | Possible side effects |
|---|---|
| Heart and lung surgery | Bleeding, infection, irregular heartbeat, long recovery |
| Chemotherapy | Hair loss, sickness, tiredness, low blood counts, heart strain (doxorubicin), kidney and bladder effects (ifosfamide) |
| Radiotherapy | Tiredness, inflammation of the lungs or oesophagus |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Major heart-lung surgery | Several days in intensive care and 1-3 weeks in hospital |
| Recovery at home | Usually 2-3 months before normal activity returns |
| Chemotherapy | Hospital visits every 3 weeks, sometimes with overnight stays for ifosfamide |
| Radiotherapy | Short daily sessions on weekdays for several weeks |
8. Outlook (prognosis)
| Situation | Approximate outlook |
|---|---|
| No surgery | Often a matter of months, typically under 1-1.5 years |
| Surgery with complete removal | Median survival can reach about 3 years, with some long-term survivors |
| Surgery plus chemotherapy or radiotherapy | Several series suggest better results than surgery alone |
| Spread to other organs | Lungs, bone, brain and kidneys; outlook usually poor |
Figures come from small series and vary widely (Assi, Kattan and Rassy, 2020). Early diagnosis, before the tumour has grown far along the vessels, is the most important factor for a better result.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| CT or MRI every 3 months at first | Detects regrowth inside the vessels or new spread |
| Echocardiogram | Checks heart function and lung pressures |
| PET-CT | When scans are unclear |
| Heart monitoring during chemotherapy | Especially with doxorubicin |
10. Living with intimal sarcoma
- Pace yourself, as breathlessness and tiredness are common during recovery
- Ask for cardiac or pulmonary rehabilitation after major surgery
- Report worsening breathlessness, chest pain or swelling promptly
- Keep an up-to-date list of medicines, including blood thinners, and carry it with you
- Ask about clinical trials, as research is active in MDM2-driven sarcomas
- Seek emotional support from sarcoma charities and specialist nurses
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is intimal sarcoma a type of blood clot? | No. It is a cancer, but it can cause clots and look like one on scans |
| Why was I first treated for a pulmonary embolism? | The two look very similar on standard CT scans, and embolism is far more common |
| Is it inherited? | No |
| Can it be cured? | A minority of people remain well for years after complete surgery |
| Does it spread? | Yes, mainly along the arteries and to the lungs, but also to other organs |
| Are there targeted treatments? | Drugs aimed at MDM2 and CDK4 are being tested in trials |
12. Questions to ask your care team
- How sure are you that this is a tumour rather than a clot?
- Has the tumour been tested for MDM2 and other gene changes?
- Can it be removed with surgery, and what does the operation involve?
- Should I have chemotherapy before or after surgery?
- Am I eligible for a clinical trial?
- What symptoms should make me contact the team urgently?
Resources
- Assi, T., Kattan, J. and Rassy, E. (2020) ‘A comprehensive review on the diagnosis and management of intimal sarcoma of the pulmonary artery’, Critical Reviews in Oncology/Hematology, 147, 102889.
- Giner, F. et al. (2023) ‘Intimal sarcoma with MDM2/CDK4 amplification and p16 overexpression: a review of histological features in primary tumor and xenograft, with immunophenotype and molecular profiling’, International Journal of Molecular Sciences, 24(8), 7535.
- Koelsche, C. et al. (2021) ‘Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature’, Modern Pathology, 34(12), pp. 2122-2129.
- Lefler, D.S. et al. (2025) ‘Sarcoma: cardiovascular and oncologic considerations: JACC: CardioOncology state-of-the-art review’, JACC: CardioOncology, 7(7), pp. 800-815.
- López Subires, S., Amondarain Amenabar, N. and Valverde, C. (2026) ‘Intimal sarcoma, review and future perspectives’, Current Opinion in Oncology, 38(4), pp. 310-318.
- Qin, J. et al. (2021) ‘Pulmonary artery intimal sarcoma – a primeval or rediscovered tumor? A report of 14 new cases with literature review’, Pathology, Research and Practice, 224, 153548.
- National Cancer Institute (2026) Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.